Altamira Therapeutics’ (NASDAQ:CYTO) Bentrio nasal spray has been approved by the Medical Device Authority of Malaysia for the protection against airborne allergens and viruses and is cleared for commercialization in that country.
The product will be commercialized through the local affiliate of Wellesta Holdings of Singapore under a previously announced marketing and distribution agreement between the two companies.
Wellesta has rights to commercialize and distribute Bentrio in India, Indonesia, Malaysia, Singapore, Taiwan and Vietnam. In addition to Malaysia, Bentrio has received clearance in Singapore, and preparations and procedures are ongoing for registration in the other countries.
“We are very pleased with the swift ‘go-to-market’ progress in Malaysia and Singapore,” Thomas Meyer, Altamira’s founder, chairman and CEO, said in a statement.
“Together with our partner, Wellesta, we look forward to making Bentrio available to consumers in these dynamic countries for the protection against airborne allergens and viruses,” he added.
As previously indicated, Altamira expects Bentrio sales in Asian markets to significantly contribute to revenue in 2022.